Inogen (INGN) Cash from Financing Activities (2013 - 2026)

Inogen's (INGN) quarterly Cash from Financing Activities came in at -$2.1 million in Q1 2026, down 108.86% year-on-year from $24.0 million in Q1 2025, and down 1035.29% on a QoQ basis from -$187000.0 in Q4 2025.

Inogen (INGN) Cash from Financing Activities (2013 - 2026) Analysis & Trends

Inogen (INGN) has 14 years of Cash from Financing Activities data on file, last reported at -$2.1 million in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 108.86% year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was -$1.9 million, a 107.91% decrease from a year earlier, with the FY2025 full-year figure at $24.2 million, up 9025.28% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at -$2.1 million, down from -$187000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for INGN reached as high as $24.0 million in Q1 2025 and fell as low as -$2.1 million in Q1 2026.
  • Historically, Cash from Financing Activities has averaged $1.5 million across 5 years, with a median of -$23500.0 in 2023.
  • Across the five-year window, Cash from Financing Activities plunged 1757.14% in 2024 and jumped 8303.86% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at -$112000.0 in 2022, then jumped by 87.5% to -$14000.0 in 2023, then plunged by 1757.14% to -$260000.0 in 2024, then grew by 28.08% to -$187000.0 in 2025, then slumped by 1035.29% to -$2.1 million in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.1 million in Q1 2026, -$187000.0 in Q4 2025, and $418000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 17.31 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -1.51 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn -888.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -260.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -451.20 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -25.00 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -26.93 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 21.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Inogen 172.68 Mn 62.51 Mn 37.86 Mn -2.12 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.12 Mn
Mar 31, 2026 -2.12 Mn
Dec 31, 2025 -187,000.00
Dec 31, 2025 -187,000.00
Sep 30, 2025 418,000.00
Sep 30, 2025 418,000.00
Mar 31, 2025 23.95 Mn
Mar 31, 2025 23.95 Mn
Dec 31, 2024 -260,000.00
Dec 31, 2024 -260,000.00
Sep 30, 2024 441,000.00
Sep 30, 2024 441,000.00
Jun 30, 2024 -201,000.00
Jun 30, 2024 -201,000.00
Mar 31, 2024 285,000.00
Mar 31, 2024 285,000.00
Dec 31, 2023 -14,000.00
Dec 31, 2023 -14,000.00
Sep 30, 2023 448,000.00
Sep 30, 2023 448,000.00